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Lipocalin family members have been implicated in development, regeneration, and pathological processes, but their roles are
unclear. Interestingly, these proteins are found abundant in the venom of the Lonomia obliqua caterpillar. Lipocalins are β-barrel
proteins,whichhavethreeconservedmotifsintheiraminoacidsequence.Oneofthesemotifswasshowntobeasequencesignature
involved in cell modulation. The aim of this study is to investigate the eﬀects of a synthetic peptide comprising the lipocalin
sequence motif in ﬁbroblasts. This peptide suppressed caspase 3 activity and upregulated Bcl-2 and Ki-67, but did not interfere
with GPCR calcium mobilization. Fibroblast responses also involved increased expression of proinﬂammatory mediators. Increase
of extracellular matrix proteins, such as collagen, ﬁbronectin, and tenascin, was observed. Increase in collagen content was also
observed in vivo. Results indicate that modulation eﬀects displayed by lipocalins through this sequence motif involve cell survival,
extracellular matrix remodeling, and cytokine signaling. Such eﬀects can be related to the lipocalin roles in disease, development,
and tissue repair.
1.Introduction
Development and regeneration are processes driven by dy-
namic regulation of extracellular matrix (ECM). ECM is
continuously exposed to physical and chemical injuries, and
its composing proteins are continuously synthesized and
secreted by ﬁbroblasts, which play a central role in regulation
oftissuehomeostasis.Thus,inyoungandhealthytissuethere
is a balance between ECM deposition and degradation, in a
well-organized and regulated process [1, 2].
Dysfunctions in deposition and remodeling of ECM
proteins hinder normal tissue repair and are observed in
several pathologies, such as chronic wound [3], sclerosis
and other ﬁbrotic diseases [4, 5], tendinopathy [6], diabetes
[7], renal disease [8], pulmonary disorders [9], and even
heart disease [10]. Many of these have involvement of
cytokines. In addition, other undesired conditions such as
chrono- and photoaging are associated with breakdown
and impaired synthesis of ECM proteins, especially collagen
[2].
Interestingly, lipocalin levels are particularly elevated in
some of these and other pathological states [11–15], as well
as in site-speciﬁc injuries [16–18]. Furthermore, expression
of lipocalins has been associated with regeneration and
tissuerepair[16–20],metamorphosis[16,21,22],pregnancy
[23], chondrogenesis [24, 25], and other processes related
to embryogenesis and postnatal development [14, 24, 26–
28]. These ﬁndings suggest those proteins play a special
role in morphogenesis. Lipocalin roles may be beyond their
particular lipophilic ligand-binding properties, given the
broadphylogeneticrangeandtissuedistributionoflipocalins
reported in these studies.
Lipocalins are among the most abundant proteins found
in the venom of the Lonomia obliqua caterpillar [29, 30].2 Journal of Toxicology
They are multifunctional proteins with a β-barrel struc-
ture, which share three characteristic conserved domains
in their primary structure, namely, motifs 1–3 [31, 32].
The involvement of motif 2 in cell modulation displayed
by lipocalins has been previously demonstrated through
a peptide mapping approach studying a toxin from L.
obliqua [33]. In this study, we investigated the eﬀects of a
peptide based on this lipocalin motif on human ﬁbroblasts,
evaluating the extracellular matrix proteins in vitro and in
vivo, mobilization of intracellular calcium, and mediators
involved in cell response.
2.MaterialsandMethods
2.1. Reagents and Antibodies. Ham’s F-12 culture medium
was purchased from Gibco BRL (Grand Island, NY, USA).
Fetal bovine serum (FBS) and trypsin-EDTA were from Cul-
tilab (Campinas, SP, Brazil). Vectashield mounting medium
was from Vector Laboratories (Burlingame, CA, USA). Mon-
oclonal antibodies to cellular ﬁbronectin, human tenascin,
andheatshockprotein47(HSP47)werefromSigma-Aldrich
(St. Louis, MO, USA). Other mouse IgG antibodies were
from Santa Cruz Biotechnologies (Santa Cruz, CA). Alexa
Fluor 488 goat anti-mouse IgG antibody was from Molecular
Probes (Eugene, OR, USA). FLIPR Calcium 4 Assay Kit was
obtained from Molecular Devices (Sunnyvale, CA, USA). All
other reagents were supplied by Sigma-Aldrich (St. Louis,
MO, USA).
2.2. Peptide Synthesis. Lipocalin motif-2-derived peptide
(pm2b)[33],withtheaminoacidsequenceYAIGYSCKDYK-
OH, was obtained in automated benchtop simultaneous
multiple solid-phase synthesizer, PSSM 8 system (Shimadzu,
Kyoto, Japan) using Fmoc solid phase. The peptide was
puriﬁed by reversed-phase chromatography semipreparative
HPLC (Shim-pack Prep-ODS, Shimadzu), and its purity
and identity were conﬁrmed by LC-MS mass spectrometry
Surveyor MSQ Plus, Thermo Fisher Scientiﬁc (San Jose, CA,
USA) and by analytical HPLC.
2.3. Cell Culture. Cultures of primary human ﬁbroblasts
were obtained from skin biopsies. Cells were grown in Ham’s
F-12 medium, supplemented with FBS (15%), ampicillin
(20mg/mL), streptomycin (20mg/mL), and gentamicin
(40mg/mL), at 37◦C in a humidiﬁed 5% CO2 incuba-
tor. Having reached conﬂuence, cells were washed three
times with phosphate-buﬀered saline (PBS), detached by
mild treatment with trypsin-EDTA, and washed with FBS-
supplemented medium. Experiments were carried out with
cells from the second passage. To evaluate ECM proteins,
ﬁbroblasts (1.15 × 105 cells) were cultured on round slides
in 24-well plates incubated with pm2b for 96h in 500μL
of medium. To obtain cell lysates, ﬁbroblasts were cultured
in 25cm2 culture ﬂasks and incubated with pm2b for 96h.
For ﬂow cytometry analysis, ﬁbroblasts (1.5 × 105 cells/mL)
were incubated for 72h with pm2b in 10% or 1% FBS-
supplemented medium. All experiments, unless indicated,
were carried out with the peptide at 230nM. Peptide vehicle
(150mM NaCl) was used as control of treatments.
2.4. Immunocytochemical Staining for ECM Proteins. Cells
were gently washed with PBS and ﬁxed for 15min in 3%
paraformaldehyde, 0.2% glutaraldehyde, 0.1M phosphate
buﬀer, pH 7.4. Then, slides were washed with PBS and
subjected to immunostaining with monoclonal antibody
anticellular ﬁbronectin, anti-HSP47, or anti-human tenascin
and secondary antibody Alexa Fluor 488, according to
manufacturer’s instructions. Cells were washed and slides
mounted with Vectashield. Slides were visualized under
ﬂuorescence microscopy (Carl Zeiss, Jena, Germany) by
200x magniﬁcation, and ten microscopic ﬁelds were anal-
ysed. Expressions of procollagen, ﬁbronectin, and tenascin
were quantiﬁed through morphometric analysis and digital
densitometry using an Image System Analyzer (Kontron
Electronic 300, Zeiss). Values were normalized to untreated
controls.
2.5. Western Blotting. Cells were lysed in RIPA buﬀer for
20minat4◦Candcentrifugedfor5minat21,000g,toobtain
soluble and insoluble extracts. The cell lysate of treated (77
and 230nM pm2b) and control ﬁbroblasts were subjected
to SDS-PAGE, using 30μg of each protein sample of soluble
extracts. Fibronectin and laminin were analyzed using the
insoluble extracts. Then, proteins were electrotransferred
to nitrocellulose membrane, which was blocked with 1%
bovine serum albumin in 20mM Tris-HCl pH 7.4, 0.15M
NaCl, and 0.05% Tween (TBS-T) and incubated in the same
buﬀer with primary antibodies for ﬁbronectin, laminin,
collagen type I, HSP47, and GADH as control. Membranes
were washed with TBS-T and incubated with secondary
antibody conjugated with alkaline phosphatase. Incuba-
tion with each antibody was according to manufacturer’s
instructions. Nitro blue tetrazolium and 5-bromo-4-chloro-
3-indolylphosphate (NBT/BCIP) substrates were used for
immunostaining. Proteins were quantiﬁed through digital
densitometry using the ImageJ software (National Institutes
of Health, USA). Values were normalized to untreated
controls.
2.6. In Vivo Treatment. BALB/c mice (20 ± 2g)werebredat
ButantanInstitute.Animalshadfreeaccesstofoodandwater
and were in a light-dark cycle of 12h. Mice were anesthetized
with ketamine (75mg/kg) and xylazine (10mg/kg) i.p. and
had the dorsum shaved. The animals were divided into
2 groups, treated with intradermal injections of a single
dose of pm2b (0.2mL, 1.15μM, n = 6) or two repeated
doses (7 days of interval, n = 4) in a delimited site on
the dorsum. Paired controls were injected with the vehicle
(saline) in a delimited site on the opposite side in the
same animal. Skin fragments of 1 × 1 c mf r o me a c hs i t e
(pm2b-treated and control) were collected in pairs of treated
mice in intervals of one, two, and twelve weeks after single
treatment, as well as one and twelve weeks after the ﬁrst
dose of repeated treatment. Skin samples were immediately
ﬁxed in 10% buﬀered-formalin for histological procedures.Journal of Toxicology 3
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Figure 1: Extracellular matrix proteins in ﬁbroblast culture. Procollagen (a), cellular ﬁbronectin (b), and tenascin (c). Primary human
ﬁbroblasts were treated with pm2b (230nM) and proteins were analyzed after 96h by immunocytochemical staining (originally 400x). Data
are representative images and expressed as mean ± SEM for triplicate measurements.
∗∗∗P < 0.001 versus control.
Mice were euthanized prior to biopsies. All procedures were
performed in compliance with the tenets of the Brazilian
Society of Laboratory Animal Science (SBCAL/COBEA) and
the institutional ethics committee.
2.7. Histological Analysis. Tissue sections of 3μm thickness
were stained with picrosirius red and examined under light
microscopy (Carl Zeiss, Jena, Germany) coupled to Kontron
300 System Image Analyzer. Quantitative analysis of collagen4 Journal of Toxicology
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Figure 2: Extracellular matrix proteins in ﬁbroblast lysate. Primary human ﬁbroblasts were treated with pm2b (77 or 230nM) and proteins
were analyzed after 96h by western blotting. Data are representative images and expressed as mean ± SEM for duplicate measurements.
∗∗∗P < 0.001,
∗∗P<0.01,
∗P < 0.05 versus control.
was done from 10 microscopic ﬁelds at 200x magniﬁcation
on ﬂat sections of each biopsy through morphometric
analysis and digital densitometry. Data were expressed as
percentage of collagen staining to total area and in function
of matched controls.
2.8. Calcium Mobilization Assay. Changes in free intracellu-
lar calcium concentration were measured by microﬂuorime-
try using the FlexStation 3 (Molecular Devices, Sunnyvale,
CA, USA) and FlexStation Calcium Assay Kit, following
manufacturer’s instructions. Fibroblasts were seeded at a
density of 5 × 104 cells per well in black-well plates with
clear bottom. Prior to experiments, cells were incubated
for 1h, at 37◦C with the calcium kit reagent in serum-free
medium. Before measurements, the following treatments
were added: ATP (10μM), thapsigargin (1μM), and pm2b
(80 or 230nM, immediately and 1h before). Both the direct
eﬀectof pm2b and alsoits inﬂuence on calcium mobilization
by thapsigargin were investigated. The inhibitory eﬀect of
BAPTA (10μM, 30min before) was used as a positive
interference control. Fluorescence was measured during
120s, at 1.52 time intervals. Measurements were obtained
as the diﬀerence between the peak intensity ﬂuorescence and
baseline.
2.9. Flow Cytometry Analysis. Cells were gently washed with
PBS and detached with trypsin-EDTA. After addition of
FBS 10%, the cells were harvested and washed twice with
PBS. Pellets were resuspended in 4% paraformaldehyde and
stored at 4◦C. Antibody labeling was done according to
manufacturer’s instructions at room temperature. Prior to
analysis, cells were permeated with 0.1% Triton X-100 for
30min, incubated for 2h with the respective antibodies for
caspase 3, Bcl-2, Ki-67- MIB-1, cytochrome c (cyt c), IL-
1β, CXCR1, CXCR2, IL-6R, or collagen-1 receptor (α2β1),
and then incubated with the secondary antibody Alexa Fluor
488 in the dark. Fluorescence-activated cell sorting (FACS)
analysis was performed on a FACSCalibur ﬂow cytometer,
Becton Dickinson (San Jose, CA, USA). For each sample, at
least10,000eventswereacquiredandthedatawereevaluated
using the Cell-Quest software.
2.10. Statistical Analysis. The diﬀerence among groups was
analyzed by one-way or two-way analysis of varianceJournal of Toxicology 5
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Figure 3: Peptide treatment increases collagen in the mice dermis. (a) Mean values of groups treated with a single dose (0.2mL, 1.15μM
pm2b, i.d.) or repeated doses compared with controls (n = 4–6). (b) Matched observations of pm2b-treated and saline-treated sites (1 ×
1cm)inthesameanimalsinsuccessiveintervalsaftertreatment.(c)Picrosirius-red-stainedsections(originally340x).Dataarerepresentative
images and expressed as mean ± SEM.
∗∗P < 0.01,
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Figure 4: Calcium mobilization in ﬁbroblasts. Fibroblasts were
treated with pm2b at diﬀerent concentrations immediately and
1h before the test, and with thapsigargin (1μM), BAPTA (10μM,
30min before), and ATP (10μM). Data are expressed as mean ±
SEM for duplicate measurements.
(ANOVA) and Student’s t-test. Data are expressed as mean ±
standard error (SEM) and representative images from each
group. Diﬀerences were considered statistically signiﬁcant
when P<0.05.
3. Results
3.1. Increased Production of ECM Proteins in Fibroblast
Culture. To evaluate if pm2b was able to modulate ﬁbroblast
response, we assessed if the peptide could interfere with the
production of ECM proteins by primary human ﬁbroblasts
in culture.
Immunoﬂuorescence results showed that treatment with
pm2b induced a signiﬁcant increase of procollagen, ﬁ-
bronectin,andtenascin,asshowninFigure 1.Incomparison
to nontreated cultures, pm2b-treated ﬁbroblasts showed
almost onefold increase in tenascin (94%) and an increase
in 49% of procollagen and 62% of ﬁbronectin. Analysis of
collagen type I, ﬁbronectin, and laminin in the cell lysates
by western blotting showed a signiﬁcant increase in all these
proteins in cultures treated with the peptide at 70 or 230nM
and a slight increase in HSP47 (Figure 2).
3.2. Increased Production of Collagen In Vivo. Since the
peptide treatment induced a change in the content of ECM
proteins in vitro, we assessed whether if pm2b was also able
to increase the amount of collagen in vivo in the mice dermis
(Figure 3). Interaction of pm2b treatment and the collagen
content was statistically signiﬁcant (two-way ANOVA, P<
0.05), either if it was lower than that observed in vitro.
Treatment with a single dose induced a mean increase of
local collagen ﬁbrils in about 10%, while with two repeated
dosesthemeanincreasewas15%(Figure 3(a)).Withasingle
dose, the higher diﬀerence to controls was observed 7 days
after treatment. The ratio between treated area and control
dropped along the time. Interestingly, in the group treated
with 2 doses of pm2b, the collagen increase lasted for 3
months (Figure 3(b)).
3.3. Calcium Mobilization. Increase of intracellular calcium
in ﬁbroblasts was observed by using ATP or thapsigargin
(Figure 4). As expected, pretreatment with BAPTA abolished6 Journal of Toxicology
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Figure 5: Diﬀerential expression of mediators involved in cell viability (a), cytokine and receptors (b). Fibroblasts were cultured with pm2b
(230nM) for 72h with 10% or 1% FBS and analyzed by FACS. Data are expressed as mean ± SEM for triplicate measurements.
∗∗∗P < 0.01,
∗∗P < 0.01,
∗P < 0.05 versus controls. ###P < 0.01, ##P < 0.01, #P < 0.05 versus controls with 10% FBS.
the eﬀect of thapsigargin. On the other hand, the peptide
investigated showed no direct eﬀect on intracellular calcium
mobilization. In addition, it did not seem to interfere with
the action of thapsigargin.
3.4. Modulation of Mediators Involved in Cell Viability and
Inﬂammation. To investigate the mechanisms underlying
ﬁbroblast responses induced by pm2b, a set of mediators
expressed by the cells in 1% and 10% FBS-supplemented
medium were analyzed. Either treated or nontreated cultures
showed diﬀerent responses in these two conditions. pm2b
promoted a synergistic modulation of mediators involved
in apoptosis, antiapoptosis, and proliferation, resulting
in a prosurvival response. As seen in Figure 5(a),p m 2 b
suppressed caspase-3 and upregulated Bcl-2 and Ki-67. As
shown in Figure 5(b), increases in CXCR1 and IL-6R were
observed only with 1% FBS. On the other hand, cyt c was
exclusively upregulated in 10% FBS-supplemented medium.
In both conditions, there was a slight increase in the
α2β1expression, but not statistically signiﬁcant. CXCR2 and
IL-1β were markedly increased in both culture conditions.
4. Discussion
It is well known that morphogenesis and other physiological
processes consist in a chain of events regulated by cross-talk
signaling between ECM cells, receptors, and signaling factors
[34]. However, lipocalin roles in these processes are not
clearly understood. Regardless of many reports describing
lipocalins as biomarkers of diseases [11] and others that cor-
relate high lipocalin expression levels with stress conditions
[35] and injury [16, 17], little is known about the biological
activities of these multifunctional proteins and how they can
modulate tissue and cell responses.
Lipocalins are classically recognized as carriers of
lipophilic molecules. However, outgrowing data on the liter-
ature have indicated they are more than that. Some authors
have suggested lipocalin motifs should play important roles
in the structure pattern and functional properties of these
proteins [31, 32, 36]. Bioinformatic analysis and peptide
mapping indicated motif 2 is implicated in cell modulation
and suggested it is a sequence signature with a role in cell
survival [33]. However, its possible eﬀects in ﬁbroblasts were
not known.
We have obtained a synthetic peptide with amino
acid sequence based on the lipocalin motif 2, found in
Lopap—an insect lipocalin from the L. obliqua caterpillar
[37]. Lopap was previously shown to have a direct eﬀect
on endothelial cells increasing the surface expression of cell
adhesion molecules, triggering IL-8 and nitric oxide release,
and displaying antiapoptotic activity [36–40]. The peptide
reproduced the eﬀects observed with the whole protein,
exhibiting an antiapoptotic activity in endothelial cells and
neutrophils, which is dependent on nitric oxide synthase
activity [33].
Herein, results demonstrate the peptide can modulate
mediators favoring a prosurvival response, with suppression
of caspase 3—a key proapoptotic enzyme, and up-regulation
of the antiapoptotic protein Bcl-2, as well as the proliferation
markerKi-67.Otherstudieshavealsoattributedtolipocalins
r o l e si nc e l ls u r v i v a li nd i ﬀerent cell lineages [41–43],
which support the hypothesis of a common property among
lipocalins. This eﬀect can be important for the lipocalin
roles in several developmental and repairing processes, for
protective response to stress, as well as for their possible
involvement in many diseases.
Interestingly, pm2b treatment increased ECM proteins
in vitro and in vivo. Fibroblasts are metabolically active
cells which major function is the production of ECM
components [1]. Our ﬁndings suggest for the ﬁrst time
a lipocalin role in ECM modulation. This ﬁnding brings
new insights to understanding the involvement of lipocalins
in the pathophysiology of diseases involving ECM deposi-
tion/remodeling defects. The diﬀerence in the amount of
collagen increase induced by pm2b in vitro and in vivo may
be due to collagen degradation by matrix metalloproteinases
or either the peptide dose used and its stability in the tissue.
Ki-67isabsentinrestingcellsandpresentduringallphasesof
cell cycle, but otherwise its role in ribosomal RNA synthesis
[44] may be related to the increase in synthesis activity
observed in ﬁbroblasts.Journal of Toxicology 7
Fibroblast modulation by pm2b was shown to involve
cytokine signaling favoring a proinﬂammatory response.
BesidesthepreviouslyreportedmodulationofIL-8byLopap
[39], results showed the induction of the IL-8 receptors.
Expression of the chemokine receptor CXCR1 was increased
only in serum-deprived cultures, while expression of its
paralog CXCR2 was increased no matter the assay condition.
IL-8 and its receptors are known to have an autocrine role
in cell survival [45]. There are also reports describing the
involvement of IL-1 [46] and IL-6/IL-6R [47] in antiapop-
totic responses. On the other hand, a local proinﬂammatory
response can contribute for healing and regeneration [48].
However, the mechanisms by which Lopap and derived
p e p t i d et r i g g e rc e l lr e s p o n s e sh a v et ob ei n v e s t i g a t e d .A s
results show, it does not seem to involve changes in calcium
transients.
To our knowledge, this is the ﬁrst report of lipocalins
modulating ﬁbroblasts and ECM proteins, which could be
directly implicated to their roles in morphogenesis and
tissue homeostasis. The involvement of growth factors and
cytokines in development and repairing process is well
described [49]. However, lipocalins may be also considered
as important players in these processes. Therefore, the mech-
anisms by which these proteins can trigger cell modulation
have to be carefully investigated. Understanding the eﬀects
of these proteins can open perspectives for their use in
prognosis and treatment of many dysfunctions involving
wound healing, tissue remodeling, and cell death.
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